SAB Biotherapeutics, Inc., was incorporated in Delaware on November 12, 2020. The company is a clinical-stage biopharmaceutical company that uses fully human polyclonal antibodies to advance a new class of immunotherapies. SAB has applied advanced genetic engineering and antibody science to develop a transchromosomal (Tc) Bovine herd that can produce fully human antibodies against specific diseases, including infectious diseases such as COVID - 19 and influenza, immune system diseases such as type 1 diabetes and organ transplantation, and cancer. SAB's multifunctional DiversitAb platform is suitable for a wide range of serious unmet needs in human diseases. It produces natural, specifically targeted, highly effective human polyclonal immunotherapy. SAB is currently advancing several clinical programs and working with the US government and global pharmaceutical companies. 

SABS